Top Suppliers:I want be here

155-91-9

155-91-9 structure
155-91-9 structure
  • Name: Sulphamoprine
  • Chemical Name: 4-amino-N-(4,6-dimethoxypyrimidin-2-yl)benzenesulfonamide
  • CAS Number: 155-91-9
  • Molecular Formula: C12H14N4O4S
  • Molecular Weight: 310.329
  • Create Date: 2018-03-26 08:00:00
  • Modify Date: 2024-01-03 23:10:50

Name 4-amino-N-(4,6-dimethoxypyrimidin-2-yl)benzenesulfonamide
Synonyms Sulfanilsaeure-(4,6-dimethoxy-pyrimidin-2-ylamid)
Sulphamoprine
Sulfadimethoxypyrimidine
2-p-Aminobenzenesulfonamido-4,6-dimethoxypyrimidine
sulphadimethoxine
sulfadimethoxine
4-Amino-N-(4,6-dimethoxy-2-pyrimidinyl)benzenesulfonamide
Benzenesulfonamide, 4-amino-N-(4,6-dimethoxy-2-pyrimidinyl)-
SDmP
sulfanilic acid-(4,6-dimethoxy-pyrimidin-2-ylamide)
6-(p-aminobenzenesulphonamido)-2,4-dimethoxypyrimidine
4-Amino-N-(4,6-dimethoxypyrimidin-2-yl)benzenesulfonamide
Sulfamoprine
ICI 3435
Sulphadimethoxypyrimidine
4-amino-N-(4,6-dimethoxy-pyrimidin-2-yl)-benzenesulfonamide
Density 1.4±0.1 g/cm3
Boiling Point 570.7±60.0 °C at 760 mmHg
Melting Point 200ºC
Molecular Formula C12H14N4O4S
Molecular Weight 310.329
Flash Point 298.9±32.9 °C
Exact Mass 310.073578
PSA 124.81000
LogP 1.41
Vapour Pressure 0.0±1.6 mmHg at 25°C
Index of Refraction 1.623

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DA9495000
CHEMICAL NAME :
Benzenesulfonamide, 4-amino-N-(4,6-dimethoxy-2-pyrimidinyl)-
CAS REGISTRY NUMBER :
155-91-9
BEILSTEIN REFERENCE NO. :
0307123
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C12-H14-N4-O4-S
MOLECULAR WEIGHT :
310.36
WISWESSER LINE NOTATION :
T6N CNJ BMSWR DZ& DO1 FO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28 gm/kg/28D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), zonal Blood - normocytic anemia Related to Chronic Data - death
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 2,149,1947 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
538 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Effects on Newborn - physical
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - stillbirth
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
825 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 11-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - skin and skin appendages
REFERENCE :
EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 21,151,1965
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2520 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2520 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 23,305,1964
Hazard Codes Xi
Risk Phrases 36/37/38-43
Safety Phrases 26-36/37-24/25-23
HS Code 2935009090

~%

155-91-9 structure

155-91-9

Literature: Rose; Tuey Journal of the Chemical Society, 1946 , p. 81,84 Full Text Show Details Braker et al. Journal of the American Chemical Society, 1947 , vol. 69, p. 3072,3075 Full Text Show Details Leitch et al. Canadian Journal of Research, Section B: Chemical Sciences, 1947 , vol. 25, p. 14,17

~%

155-91-9 structure

155-91-9

Literature: Leitch et al. Canadian Journal of Research, Section B: Chemical Sciences, 1947 , vol. 25, p. 14,17
Precursor  2

DownStream  0

HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%